314 related articles for article (PubMed ID: 27480449)
1. Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients.
Bonfigli AR; Boemi M; Festa R; Bonazzi P; Brandoni G; Spazzafumo L; Olivieri F; Ceriello A; Genovese S; Testa R
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):893-8. PubMed ID: 27480449
[TBL] [Abstract][Full Text] [Related]
2. Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
Zullo A; Fiorini G; Scaccianoce G; Portincasa P; De Francesco V; Vassallo R; Urban F; Monica F; Mogavero G; Amato A; Vaira D
J Gastrointestin Liver Dis; 2019 Mar; 28(1):11-14. PubMed ID: 30851166
[TBL] [Abstract][Full Text] [Related]
3. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
[TBL] [Abstract][Full Text] [Related]
4. Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication.
De Francesco V; Ridola L; Hassan C; Bellesia A; Alvaro D; Vaira D; Zullo A
J Gastrointestin Liver Dis; 2016 Jun; 25(2):147-50. PubMed ID: 27308644
[TBL] [Abstract][Full Text] [Related]
5. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.
Liou JM; Chen PY; Luo JC; Lee JY; Chen CC; Fang YJ; Yang TH; Chang CY; Bair MJ; Chen MJ; Hsu YC; Hsu WF; Chang CC; Lin JT; Shun CT; El-Omar EM; Wu MS;
Gastroenterology; 2018 Oct; 155(4):1109-1119. PubMed ID: 29964036
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of Helicobacter pylori eradication rates of twice-versus four-times-daily amoxicillin administered with proton pump inhibitor and clarithromycin: a randomized study.
Kim SY; Lee SW; Jung SW; Koo JS; Yim HJ; Park JJ; Chun HJ; Lee HS; Choi JH; Kim CD; Ryu HS
Helicobacter; 2008 Aug; 13(4):282-7. PubMed ID: 18665938
[TBL] [Abstract][Full Text] [Related]
7. Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study.
Nseir W; Diab H; Mahamid M; Abu-Elheja O; Samara M; Abid A; Mograbi J
Aliment Pharmacol Ther; 2012 Aug; 36(3):231-8. PubMed ID: 22646167
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection.
Mestrovic A; Perkovic N; Bozic J; Pavicic Ivelja M; Vukovic J; Kardum G; Puljiz Z; Tonkic A
PLoS One; 2020; 15(12):e0244500. PubMed ID: 33378403
[TBL] [Abstract][Full Text] [Related]
9. A novel hybrid first-line therapy for H. pylori eradication: results of a pilot study.
De Francesco V
J Gastrointestin Liver Dis; 2019 Mar; 28(1):129-130. PubMed ID: 30851183
[No Abstract] [Full Text] [Related]
10. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
[TBL] [Abstract][Full Text] [Related]
11. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial.
Chen KY; Lin TJ; Lin CL; Lee HC; Wang CK; Wu DC
World J Gastroenterol; 2015 Sep; 21(36):10435-42. PubMed ID: 26420970
[TBL] [Abstract][Full Text] [Related]
12. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
[TBL] [Abstract][Full Text] [Related]
13. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori.
Noda H; Noguchi S; Yoshimine T; Goji S; Adachi K; Tamura Y; Izawa S; Ebi M; Yamamoto S; Ogasawara N; Funaki Y; Sasaki M; Kasugai K
J Gastrointestin Liver Dis; 2016 Sep; 25(3):283-8. PubMed ID: 27689190
[TBL] [Abstract][Full Text] [Related]
14. Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection.
Wu IC; Wu DC; Hsu PI; Lu CY; Yu FJ; Wang TE; Chang WH; Chen JJ; Kuo FC; Wu JY; Wang WM; Bair MJ
Helicobacter; 2007 Dec; 12(6):633-7. PubMed ID: 18001406
[TBL] [Abstract][Full Text] [Related]
15. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
Georgopoulos SD; Xirouchakis E; Martinez-Gonzales B; Zampeli E; Grivas E; Spiliadi C; Sotiropoulou M; Petraki K; Zografos K; Laoudi F; Sgouras D; Mentis A; Kasapidis P; Michopoulos S
Eur J Intern Med; 2016 Jul; 32():84-90. PubMed ID: 27134145
[TBL] [Abstract][Full Text] [Related]
16. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication.
Tepeš B; Vujasinović M; Šeruga M; Stefanovič M; Forte A; Jeverica S
Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):676-83. PubMed ID: 26862930
[TBL] [Abstract][Full Text] [Related]
17. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
[TBL] [Abstract][Full Text] [Related]
18. Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients.
Demir M; Gokturk HS; Ozturk NA; Arslan H; Serin E; Yilmaz U
South Med J; 2009 Nov; 102(11):1116-20. PubMed ID: 19864973
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study.
Lim JH; Lee DH; Choi C; Lee ST; Kim N; Jeong SH; Kim JW; Hwang JH; Park YS; Lee SH; Shin CM; Jo HJ; Jang ES; Song Is; Jung HC
Helicobacter; 2013 Jun; 18(3):180-6. PubMed ID: 23305083
[TBL] [Abstract][Full Text] [Related]
20. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
